C. Corpechot

发表

Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia

J. Weissenbach, H. Chabriat, E. Cabanis, 1996, Nature.

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

E. Vicaut, D. Klatzmann, F. Berenbaum, 2018, Annals of the rheumatic diseases.

Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients

J. Weissenbach, H. Chabriat, C. Cruaud, 1997, The Lancet.

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

G. Hirschfield, U. Beuers, D. Jones, 2017, Journal of hepatology.

Genetic factors of susceptibility and of severity in primary biliary cirrhosis.

S. Heath, F. Matsuda, Y. Chrétien, 2008, Journal of hepatology.

Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC

M. Ziol, V. de Lédinghen, P. Marcellin, 2006, Hepatology.

Elastography-based assessment of primary biliary cirrhosis staging.

C. Corpechot, R. Poupon, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Large‐scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis

F. Carrat, O. Chazouilleres, C. Corpechot, 2017, Hepatology.

Notch3 Mutations in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), a Mendelian Condition Causing Stroke and Vascular Dementia

J. Weissenbach, H. Chabriat, E. Cabanis, 1997, Annals of the New York Academy of Sciences.

Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis.

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2012, Journal of hepatology.

The Role of Fibrates in Primary Biliary Cholangitis

C. Corpechot, 2019, Current Hepatology Reports.

Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease

N. Rioux-Leclercq, K. Dahan, E. Daugas, 2015, Medicine.

Kinetic Analyses of Antiviral Suppression by NS5A Inhibitors Reveal Early and Potent Inhibition of Viral Assembly and Release of Infectious Virus The rs2294918 K434E PNPLA3 Polymorphism is associated with Nonalcoholic Fatty Liver and Steatohepatitis

J. Talwalkar, A. Burroughs, F. Nevens, 2013 .

Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.

A. Grigorian, C. Corpechot, R. Poupon, 2015, Clinics and research in hepatology and gastroenterology.

Elastography in hepatology.

C. Corpechot, R. Poupon, L. Abenavoli, 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA‐treated patients with primary biliary cirrhosis

Y. Chrétien, D. Wendum, C. Corpechot, 2004, Liver international : official journal of the International Association for the Study of the Liver.

Gender and liver: Is the liver stiffness weaker in weaker sex?

C. Corpechot, R. Poupon, A. Naggar, 2006, Hepatology.

Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis.

D. Wendum, C. Corpechot, V. Barbu, 2002, The American journal of pathology.

A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

V. de Lédinghen, P. Potier, F. Zoulim, 2018, The New England journal of medicine.

Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy.

A. Montano‐Loza, C. Corpechot, A. Montaño-Loza, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

New treatments/targets for primary biliary cholangitis

O. Chazouilleres, C. Corpechot, R. Poupon, 2019, JHEP reports.

Fetal microchimerism in primary biliary cirrhosis.

O. Chazouilleres, C. Corpechot, V. Barbu, 2000, Journal of hepatology.

Range of Normal Liver stiffness and Predictors of Suspected Advanced Fibrosis in Apparently Healthy Individuals: A Pooled Analysis of 16,082 Participants

M. Kumar, V. Wong, K. Chayama, 2018 .

Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium.

D. Wendum, C. Corpechot, R. Poupon, 2009, Gastroenterology.

Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities

P. Potier, Y. Chrétien, O. Chazouilleres, 2020, JHEP reports : innovation in hepatology.

Promoter polymorphism of the CD14 endotoxin receptor gene and primary biliary cirrhosis

C. Corpechot, R. Poupon, 2002, Hepatology.

University of Birmingham Risk Stratification in autoimmune cholestatic liver diseases

P. Trivedi, G. Hirschfield, C. Corpechot, 2015 .

Treatment of primary biliary cirrhosis

C. Corpechot, R. Poupon, 2000, Bailliere's best practice & research. Clinical gastroenterology.

Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid

C. Corpechot, 2016, Seminars in Liver Disease.

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid

F. Nevens, K. Lindor, C. Ponsioen, 2022, Alimentary pharmacology & therapeutics.

Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis

O. Chazouilleres, C. Corpechot, L. Arrivé, 2022, JHEP reports : innovation in hepatology.

Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium

X. Causse, O. Chazouilleres, C. Corpechot, 2020, European journal of gastroenterology & hepatology.

Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis

A. Lohse, O. Chazouilleres, C. Corpechot, 2016, Gut.

Primary biliary cirrhosis and bile acids.

C. Corpechot, 2012, Clinics and research in hepatology and gastroenterology.

Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2008, Hepatology.

Granulocytic sarcoma of the jejunum: a rare cause of small bowel obstruction

R. Modigliani, X. Mariette, C. Corpechot, 1998, American Journal of Gastroenterology.

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.

V. de Lédinghen, F. Carrat, F. Nevens, 2022, Journal of hepatology.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY BILIARY CHOLANGITIS.

V. de Lédinghen, P. Potier, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

Clinical Trials in PBC Going Forward

C. Corpechot, 2019, Seminars in Liver Disease.

Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add‐on in primary biliary cholangitis with incomplete UDCA response

A. Rousseau, O. Chazouilleres, C. Corpechot, 2019, Alimentary pharmacology & therapeutics.

Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.

O. Chazouilleres, C. Corpechot, R. Poupon, 2011, Journal of hepatology.

Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival

D. Samuel, K. Boudjema, J. Gugenheim, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Fibrosis and Prognosis Assessment Using Liver Stiffness in Patients with PBC and PSC

C. Corpechot, 2020 .

The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis.

A. Floreani, Y. Chrétien, P. Trivedi, 2019, The American journal of gastroenterology.

Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis.

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2010, Journal of hepatology.

Bezafibrate in Primary Biliary Cholangitis.

A. Rousseau, O. Chazouilleres, C. Corpechot, 2018, The New England journal of medicine.

Identification of a Novel 974C→G Nonsense Mutation of the MRP2/ABCC2 Gene in a Patient with Dubin-Johnson Syndrome and Analysis of the Effects of Rifampicin and Ursodeoxycholic Acid on Serum Bilirubin and Bile Acids

F. Matsuda, D. Wendum, C. Corpechot, 2006, The American Journal of Gastroenterology.

University of Birmingham Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis

A. Burroughs, F. Nevens, K. Lindor, 2014 .

ABCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome

O. Chazouilleres, C. Corpechot, V. Barbu, 2022, JHEP reports : innovation in hepatology.

Low Phospholipid-Associated Cholelithiasis (LPAC)

A. Floreani, C. Corpechot, 2021, Diseases of the Liver and Biliary Tree.

Genotype‐phenotype relationships in the low‐phospholipid‐associated cholelithiasis syndrome: A study of 156 consecutive patients

P. Böelle, Y. Chrétien, O. Chazouilleres, 2013, Hepatology.

Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2006, Hepatology.

Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis.

B. Galy, D. Wendum, C. Corpechot, 1999, The American journal of pathology.

Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis.

J. Barkun, A. Barkun, A. Floreani, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Radiologic Course of Primary Sclerosing Cholangitis: Assessment by Three-Dimensional Magnetic Resonance Cholangiography and Predictive Features of Progression

F. Carrat, O. Chazouilleres, C. Corpechot, 2013 .

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis

T. Berg, F. Carrat, P. Potier, 2021, Alimentary pharmacology & therapeutics.

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.

F. Nevens, K. Lindor, C. Ponsioen, 2020, The American journal of gastroenterology.

Factors Associated With Progression and Outcomes of Early-stage Primary Biliary Cholangitis.

F. Nevens, K. Lindor, C. Ponsioen, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

F. Nevens, K. Lindor, C. Ponsioen, 2019, Alimentary pharmacology & therapeutics.

Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history

N. LaRusso, F. Nevens, K. Lindor, 2018, Hepatology.

University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

A. Burroughs, F. Nevens, K. Lindor, 2022 .

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

A. Burroughs, F. Nevens, K. Lindor, 2014, Gastroenterology.

Noninvasive elastography‐based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

F. Carrat, O. Chazouilleres, D. Wendum, 2012, Hepatology.

Significance of antibodies to soluble liver antigen/liver pancreas: a large French study

E. Ballot, O. Chazouilleres, C. Corpechot, 2009, Liver international : official journal of the International Association for the Study of the Liver.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION.

V. de Lédinghen, J. Dumortier, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.

V. Paradis, P. Böelle, F. Durand, 2014, Clinics and research in hepatology and gastroenterology.

Levels of Alkaline Phosphatase and Bilirubin are Surrogate Endpoints of Outcomes of Patients with Primary Biliary Cirrhosis – an International Follow-up Study Short title : Alkaline phosphatase and bilirubin as surrogate endpoints in PBC

A. Burroughs, F. Nevens, K. Lindor, 2014 .

Clinical Practice Guidelines EASL Clinical Practice Guidelines : The diagnosis and management of patients with primary biliary cholangitis q European Association for the Study of the Liver ⇑

G. Hirschfield, U. Beuers, D. Jones, 2017 .

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.

F. Carrat, F. Nevens, F. Rauchfuß, 2020, Journal of hepatology.

Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.

F. Nevens, A. Floreani, J. Dumortier, 2019, Gastroenterology.

Hypoxia‐induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis

D. Wendum, C. Corpechot, V. Barbu, 2002, Hepatology.

Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis

O. Chazouilleres, C. Corpechot, L. Arrivé, 2018, European Radiology.

Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis.

F. Nevens, K. Lindor, A. Floreani, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Reply: To PMID 24389304.

O. Chazouilleres, C. Corpechot, 2014, Gastroenterology.

Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles

D. Thabut, A. Cadoret, G. Feldmann, 2015, Hepatology.

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis

F. Nevens, K. Lindor, C. Ponsioen, 2019, Gut.

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals

M. Kumar, V. Wong, V. de Lédinghen, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis

H. Sokol, O. Chazouilleres, C. Corpechot, 2019, Gut.

Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.

D. Maucort-Boulch, J. Dumortier, J. Scoazec, 2015, Journal of hepatology.

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

F. Nevens, K. Lindor, C. Ponsioen, 2019, Journal of hepatology.

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.

Y. Chrétien, O. Chazouilleres, D. Wendum, 2010, Gastroenterologie clinique et biologique.

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.

F. Carrat, Y. Chrétien, C. Corpechot, 2005, Gastroenterology.

Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.

F. Carrat, O. Chazouilleres, D. Wendum, 2014, Gastroenterology.

Genetic contribution of ABCC2 to Dubin‐Johnson syndrome and inherited cholestatic disorders

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2020, Liver international : official journal of the International Association for the Study of the Liver.

The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study

F. Lammert, M. Krawczyk, C. Corpechot, 2016, Alimentary pharmacology & therapeutics.

Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.

F. Nevens, K. Lindor, A. Floreani, 2022, Gastroenterology.

Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.

L. Sandrin, M. Sasso, O. Chazouilleres, 2016, Ultrasound in medicine & biology.

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study

M. Ziol, V. Paradis, V. Vilgrain, 2009, Hepatology.

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

F. Carrat, C. Corpechot, R. Poupon, 2000, Hepatology.

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Andrew K Burroughs, Pietro Invernizzi, Frederik Nevens, 2015, Gut.

Reply:

O. Chazouilleres, C. Corpechot, R. Poupon, 2009 .

Geotherapeutics of primary biliary cirrhosis: Bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom

C. Corpechot, R. Poupon, 2007, Hepatology.

Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.

F. Carrat, C. Corpechot, R. Poupon, 2002, Gastroenterology.

Therapy of primary biliary cirrhosis

C. Corpechot, R. Poupon, R. Poupon, 2000 .

[111] BIOCHEMICAL RESPONSE TO UDCA AND LONG-TERM RISK OF DEATH OR LIVER TRANSPLANTATION IN PBC

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2007 .

Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.

F. Carrat, A. Tanaka, H. Takikawa, 2021, Journal of hepatology.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

F. Nevens, K. Lindor, C. Ponsioen, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

F. Nevens, K. Lindor, C. Ponsioen, 2018, The American Journal of Gastroenterology.

Features, prognosis and management of primary biliary cirrhosis in the era of ursodeoxycholic acid

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2009 .

Baveno-VI-Guided Prediction of Esogastric Varices in Primary Biliary Cholangitis.

X. Causse, O. Chazouilleres, C. Corpechot, 2019, The American journal of gastroenterology.

Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe

F. Nevens, K. Lindor, C. Ponsioen, 2022, European journal of gastroenterology & hepatology.

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

F. Nevens, K. Lindor, C. Ponsioen, 2022, The American journal of gastroenterology.

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.

F. Nevens, K. Lindor, C. Ponsioen, 2020, The American journal of gastroenterology.

Primary biliary cirrhosis: is there still a place for histological evaluation?

D. Wendum, C. Corpechot, 2013, Clinics and research in hepatology and gastroenterology.

Noninvasive Evaluation of Fibrosis and Portal Hypertension in Primary Biliary Cholangitis.

C. Corpechot, 2022, Clinics in liver disease.

Bilirubin is predictive of transplant-free survival even within the normal range in primary biliary cholangitis patients

N. LaRusso, F. Nevens, K. Lindor, 2017 .

Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements

F. Nevens, K. Lindor, C. Ponsioen, 2018 .

P364 CHARACTERIZATION AND OUTCOME OF ANTIMITOCHONDRIAL TYPE 2-POSITIVE PATIENTS WITHOUT A DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS: A FRENCH NATIONWIDE PROSPECTIVE STUDY

F. Carrat, O. Chazouilleres, C. Corpechot, 2014 .

Bezafibrate Add-On Therapy Improves Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis: A Japanese Nationwide Cohort Study.

F. Carrat, A. Tanaka, H. Takikawa, 2021, Gastroenterology & hepatology.

Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

F. Nevens, K. Lindor, C. Ponsioen, 2020, European journal of gastroenterology & hepatology.

Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists

P. Trivedi, G. Hirschfield, C. Corpechot, 2015, Hepatology.

Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases.

C. Corpechot, 2016, Clinics in liver disease.

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

P. Potier, F. Zoulim, A. Rousseau, 2017 .

FRI-010-Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with an improvement of fibrometer and fibrometer-VCTE, two high-accuracy non-invasive fibrosis tests extensively validated in frequent chronic liver diseases

A. Rousseau, O. Chazouilleres, C. Corpechot, 2019, Journal of Hepatology.

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.

O. Chazouilleres, C. Corpechot, R. Poupon, 2018, Clinics and research in hepatology and gastroenterology.

Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis

A. Rousseau, O. Chazouilleres, C. Corpechot, 2018, Gut.

Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome

D. Samuel, J. Dumortier, O. Guillaud, 2022, Liver international : official journal of the International Association for the Study of the Liver.

TNF-α antagonist infliximab for aseptic abscess syndrome.

C. Corpechot, A. Mékinian, O. Fain, 2019, Presse medicale.

Long‐term outcome of liver transplantation for autoimmune hepatitis: A French nationwide study over 30 years

D. Maucort-Boulch, D. Samuel, J. Dumortier, 2023, Liver international : official journal of the International Association for the Study of the Liver.

Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis.

A. Lohse, E. Vettorazzi, O. Chazouilleres, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis

A. Quaas, A. Lohse, O. Chazouilleres, 2016, PloS one.

Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis.

O. Chazouilleres, C. Corpechot, L. Arrivé, 2019, Clinics and research in hepatology and gastroenterology.

Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis

D. Samuel, K. Boudjema, C. Duvoux, 2023, JHEP reports : innovation in hepatology.

Disease recurrence after liver transplantation for NAFLD cirrhosis is ineluctable

D. Samuel, K. Boudjema, C. Duvoux, 2023, JHEP Reports.

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

F. Nevens, K. Lindor, C. Ponsioen, 2023, Liver international : official journal of the International Association for the Study of the Liver.

A Brief Reflection on Continuous vs Binary Risk Indicators in Primary Biliary Cholangitis.

O. Chazouilleres, C. Corpechot, 2019, The American journal of gastroenterology.

Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.

A. Rousseau, O. Chazouilleres, C. Corpechot, 2020, Journal of Hepatology.

Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment

F. Nevens, K. Lindor, C. Ponsioen, 2017 .

The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time

F. Nevens, K. Lindor, C. Ponsioen, 2017 .

The GLOBE score identifies PBC patients at increased risk of liver transplantation or death during follow-up

F. Nevens, K. Lindor, C. Ponsioen, 2016 .

Expanding the mutational spectrum of the ABCB4 gene in inherited adult cholestatic liver disorders with four novel pathogenic variants.

C. Corpechot, V. Barbu, J. Delaunay, 2019, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[Autoimmune hepatitis: diagnostic and therapeutic up-to-date].

C. Corpechot, O. Chazouilleres, 2010, La Revue de medecine interne.

Acute renal failure associated with nonfulminant hepatitis A viral infection.

C. Corpechot, P. Opolon, F. Lunel, 1996, The American journal of gastroenterology.

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

B. Leggett, F. Nevens, K. Kowdley, 2023, Hepatology.

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

F. Carrat, C. Corpechot, R. Poupon, 2000, Hepatology.

Protective potential of the gallbladder in primary sclerosing cholangitis

E. Gonzalez-Sanchez, O. Chazouilleres, D. Wendum, 2022, JHEP reports : innovation in hepatology.

Primary biliary cirrhosis: proposal for a new simple histological scoring system

P. Böelle, P. Bedossa, E. Zafrani, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC

O. Chazouilleres, C. Corpechot, L. Arrivé, 2021, Alimentary pharmacology & therapeutics.

Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?

O. Chazouilleres, C. Corpechot, V. Barbu, 2001, Journal of hepatology.

Low Phospholipid-Associated Cholelithiasis (LPAC)

A. Floreani, C. Corpechot, 2021, Diseases of the Liver and Biliary Tree.

Quality of life and illness perception in primary biliary cirrhosis: a controlled cross-sectional study.

F. Zenasni, S. Sultan, O. Chazouilleres, 2015, Clinics and research in hepatology and gastroenterology.

Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium.

D. Wendum, C. Corpechot, R. Poupon, 2009, Gastroenterology.

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.

Y. Chrétien, O. Chazouilleres, D. Wendum, 2010, Gastroenterologie clinique et biologique.

Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis

Y. Chrétien, O. Chazouilleres, C. Corpechot, 2008, Hepatology.

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

David C. Jones, V. de Lédinghen, F. Carrat, 2023, Hepatology.

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

F. Nevens, K. Lindor, C. Ponsioen, 2019, Journal of hepatology.

Genotype‐phenotype relationships in the low‐phospholipid‐associated cholelithiasis syndrome: A study of 156 consecutive patients

P. Böelle, Y. Chrétien, O. Chazouilleres, 2013, Hepatology.

Primary biliary cirrhosis and bile acids.

C. Corpechot, 2012, Clinics and research in hepatology and gastroenterology.

Radiologic course of primary sclerosing cholangitis: Assessment by three‐dimensional magnetic resonance cholangiography and predictive features of progression

F. Carrat, O. Chazouilleres, C. Corpechot, 2014, Hepatology.

Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid

C. Corpechot, 2016, Seminars in Liver Disease.

Primary biliary cirrhosis: is there still a place for histological evaluation?

D. Wendum, C. Corpechot, 2013, Clinics and research in hepatology and gastroenterology.

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

G. Hirschfield, C. Corpechot, E. Zigmond, 2024, The New England journal of medicine.

Noninvasive elastography‐based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

F. Carrat, O. Chazouilleres, D. Wendum, 2012, Hepatology.

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

Bachirou O Taddé, U. Akarca, C. Corpechot, 2023, The New England journal of medicine.

University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

K. Lindor, A. Floreani, P. Trivedi, 2022 .

Clinics and research in hepatology and gastroenterology

ScienceDirect, M. Rudler, X. Causse, 2011 .

Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with Primary Biliary Cholangitis- an ELTR study

C. Duvoux, T. Decaens, H. Metselaar, 2024, JHEP Reports.

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study

M. Ziol, V. Paradis, V. Vilgrain, 2009, Hepatology.

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis

A. Floreani, P. Trivedi, G. Hirschfield, 2024, JHEP Reports.

Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.

A. Floreani, P. Trivedi, C. Corpechot, 2024, Journal of hepatology.

THE STUDY OF THE LIVER

Justus J. Bürgi, Joël L. Lavanchy, L. Alberio, 2023 .

Intrahepatic Cholestasis Owing to a Novel Heterozygous ABCG8 Mutation and SLC4A2 Polymorphism With Favorable Outcome Under Ursodeoxycholic Acid.

D. Ciocan, C. Corpechot, D. Rainteau, 2019, The American journal of gastroenterology.